

Image-Assisted Microvessel-on-a-Chip Platform for Studying Cancer Cell Transendothelial Migration Dynamics

Cristina Bertulli^{aΔ}, Magda Gerigk^{bΔ}, Nicholas Piano^b, Ye Liu^b, Duo Zhang^b, Thomas Müller^{c,d}, Tuomas J Knowles^{c,d} and Yan Yan Shery Huang^{b*}

^a Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, UK

^b Department of Engineering, University of Cambridge, Cambridge CB2 1PZ, UK


^c Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK

^d Present address: Fluidic Analytics Ltd., Cambridge CB4 3NP, UK

Δ These authors contributed equally to this project.

* corresponding: yysh2@cam.ac.uk

Supplementary Information



c)

	Zheng <i>et al.</i>	Zervantonakis <i>et al.</i>	Jeon <i>et al.</i>	Funamoto <i>et al.</i>	Current work	Current work
Cell type	HUVEC	HUVEC (in presence of cancer cells)	hMVEC	HUVEC	EA.hy926	HUVEC
Cross-section	circular	width of 500 μm , height of 120 μm	width of 500 μm , height of 120 μm	width of 500 μm , height of 150 μm	Rounded 120-150 μm	Rounded 100-120 μm
Collagen concentration [mg/ml]	6-10	2.5	2	2.5	2	2
Permeability [$\times 10^{-6}$ cm/s]	4.1 ± 0.5	7.5 ± 0.93	3.7 ± 0.59	2.9 ± 1.2	59 ± 12	12 ± 2.4

Figure SI.1: Diffusion measurements for differences in vessel quality between microvessel formed by either EA.hy926 or HUVE cells. a) fluorescent microscope images at 0, 5 and 15 minutes after the injection of 70kDa FITC-dextran for EA.hy926 and HUVE cells. b) Typical x-directional profiles of the normalized fluorescence intensity over 15 min of the infusion 70 kDa FITC-dextran for EA.hy926 (n=4) and HUVECs (n=3). c) comparison of 70 kDa FITC-dextran permeability values for different microfluidic systems between literature and the current work. All scale bars: 100 μm .




Figure SI.2: Cell number-dependent transendothelial migration in the EA.hy926 microfluidic system. a) Total number of cancer cells (MDA-MB-231) present in the field of view over time, for ten samples. b) The average number of cells which transmigrated through the endothelial barrier *vs* the average number of cancer cells in the channel and at the barrier, for each sample. The error bars indicate the maximum and minimum values of the fluctuation in the cell number over time. The red box indicates that transmigration did not occur. The data points (black dots) were fitted with a straight line with intercept set to zero; the equation of the fitting line is indicated. c) Number of cancer cells present at the barrier over time, for ten samples where cells migrated to the barrier. d) The average number of cells that crossed the endothelial barrier *vs* the average number of cancer cells at the endothelial barrier, for ten samples. The error bars indicate the maximum and minimum values of the fluctuation in the number of cells over time. The red box indicates that transmigration did not occur. The data points indicating TEM events (black dots) were fitted with a straight line with intercept set to zero; the equation of the fitting line is indicated.

MDA-MB-231

LM2-4175




Figure SL3: Comparison of our data on cancer transendothelial migration, obtained using a microvessel-on-a-chip platform, with *in vivo* and *in vitro* studies performed within 24 hr. a) Plot showing the comparison of our data (red dots and black dots fitted with straight blue line) with *in vitro* microfluidic studies done by Jeon *et al*²⁹ (triangles) and by Chen *et al*³⁰ (magenta lines), *in vitro* trans-well studies performed by Gupta *et al*²⁶ (star) and *in vivo* zebrafish studies performed by Stoletov *et al*²⁸ (orange line). b) Plot from showing the comparison of our data (red dots and black dots fitted with a straight blue line) with *in vitro* trans-well studies performed by Gupta *et al*²⁶ (star) and *in vivo* mouse studies done by Gupta *et al*²⁶ (orange line). The experimental data obtained from other publications were multiplied by the normalisation factor ($\text{Area_barrier_study}/\text{Area_barrier_paper}$). Area_barrier is the area of the endothelial barrier interfacing with the collagen matrix; this represents the only accessible area for the cancer cells to transmigrate into the collagen gel. In our study, $\text{area_barrier_study}=0.015\text{mm}^2$; in Jeon *et al*²⁹ $\text{area_barrier_paper}=0.03\text{mm}^2$; in Gupta *et al*²⁶ $\text{area_barrier_paper}=0.44\text{mm}^2$. For the study of Chen *et al*³⁰ the slope of the lines ($N_{\text{av_extadhesive}}=0.1N_{\text{av_barrier}}$ and $N_{\text{av_exttrapped}}=0.5N_{\text{av_barrier}}$) were calculated considering that 10% of the adhesive cancer cells and 50% of trapped cells that crossed the endothelial barrier, as cited in their work. For the study of Stoletov *et al*²⁸, the slope of the line ($N_{\text{av_ext}}=0.3N_{\text{av_barrier}}$) was calculated considering that 30% of the cancer cells extravasated, as cited in their work. For the study of Gupta *et al*²⁶ the slope of the line ($N_{\text{av_ext}}=0.8N_{\text{av_barrier}}$) was calculated by considering the different extravasation potential between MDA-MB-231 and LM2-4175 cells as cited in their work ($0.3*100/35$).

	<i>Yeon et al.</i>	<i>Jeon et al.</i>	<i>Chen et al.</i>	<i>Morgan et al.</i>	<i>Wong & Searson</i>	<i>Zheng et al</i>	<i>Chrobak et al</i>	Current work
Microvessel-on-a-chip preparation								
Vessel formation	self-organization and migration	straightforward seeding	vasculogenesis	straightforward seeding	straightforward seeding	straightforward seeding	straightforward seeding	straightforward seeding
Cell seeding method	pipette injection	pipette injection	pressure drop	pipette injection	gravity-driven flow	pipette injection	pipette injection	pipette injection
Type of vasculature	network	single vessel	network	network	single vessel	network	single vessel	single vessel
Time of vessel formation (after cell seeding)	5 days	2 days	2-4 days	24 hr	24 hr	3 days	2 days	16 hr
Vessel size [μm]	various (widths of 50 to 200)	width of 120	\varnothing 8-96	\varnothing 100	\varnothing 150	150 x 120	\varnothing 100	\varnothing100
Vessel geometry	random (ladder-type)	standardized	random	standardized	standardized	standardized	standardized	standardized
Co-culture	possible	possible	possible	possible	possible	possible	possible	possible
Microfluidic platform qualities and properties								
Type of ECM used	fibrinogen + aprotinin + collagen type I	collagen type I (2 mg/ml)	fibrinogen (5 or 10 mg/ml)	collagen type I (various concentrations)	collagen type I (7 mg/ml)	collagen type I (6-10 mg/ml)	collagen type I (3 or 6.5 mg/ml)	collagen type I (2 mg/ml)
Life-cell imaging of cellular behaviour	not incorporated	not incorporated	incorporated (approx. 4 hr)	incorporated (1 hr or 2-3 days)	incorporated (>10hr)	Incorporated	not incorporated	incorporated (15-16 hr)
Cell dynamics analysis	not incorporated	incorporated	not incorporated	not incorporated	not incorporated	not incorporated	not incorporated	incorporated

Table SI.1: Comparison of microfluidic systems created for microvessel formation. All of the presented systems use PDMS-based devices with incorporated ECM.